CN110402249A - 外核苷酸酶抑制剂及其使用方法 - Google Patents

外核苷酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN110402249A
CN110402249A CN201780087047.8A CN201780087047A CN110402249A CN 110402249 A CN110402249 A CN 110402249A CN 201780087047 A CN201780087047 A CN 201780087047A CN 110402249 A CN110402249 A CN 110402249A
Authority
CN
China
Prior art keywords
alkyl
compound
alkylene
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087047.8A
Other languages
English (en)
Chinese (zh)
Inventor
R.J.比耶多
J.李
陈丽晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deqi Medical Co ltd
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CN110402249A publication Critical patent/CN110402249A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780087047.8A 2016-12-22 2017-12-21 外核苷酸酶抑制剂及其使用方法 Pending CN110402249A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662437935P 2016-12-22 2016-12-22
US201662437915P 2016-12-22 2016-12-22
US62/437935 2016-12-22
US62/437915 2016-12-22
US201762555791P 2017-09-08 2017-09-08
US62/555791 2017-09-08
PCT/US2017/067980 WO2018119284A1 (en) 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN110402249A true CN110402249A (zh) 2019-11-01

Family

ID=62627279

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087047.8A Pending CN110402249A (zh) 2016-12-22 2017-12-21 外核苷酸酶抑制剂及其使用方法

Country Status (12)

Country Link
US (3) US10570167B2 (https=)
EP (1) EP3558998A4 (https=)
JP (1) JP7138351B2 (https=)
KR (1) KR102638592B1 (https=)
CN (1) CN110402249A (https=)
AU (1) AU2017382888B2 (https=)
CA (1) CA3047988A1 (https=)
IL (1) IL267291B2 (https=)
MX (1) MX383880B (https=)
NZ (1) NZ754171A (https=)
TW (1) TWI766923B (https=)
WO (1) WO2018119284A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112888696A (zh) * 2018-06-21 2021-06-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
KR102638592B1 (ko) * 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
MY202018A (en) 2017-07-31 2024-03-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
IL304348B2 (en) 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
CN113795267A (zh) 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US20220251134A1 (en) * 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
WO2020257429A1 (en) * 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
JP7557522B2 (ja) 2019-07-16 2024-09-27 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
PL4051688T3 (pl) 2019-10-30 2025-09-22 Oric Pharmaceuticals, Inc. Inhibitory cd73
JP7381913B2 (ja) * 2021-10-13 2023-11-16 ダイキン工業株式会社 有害生物防除組成物
EP4422643A4 (en) * 2021-10-26 2025-11-26 Southern Res Inst DEVELOPMENT OF NEW CLOFARABINE ANALOGUES FOR CANCER THERAPY
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008669B1 (ko) 1991-04-24 1996-06-28 야마사 쇼오유 가부시끼가이샤 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체
AU5449094A (en) 1992-11-02 1994-05-24 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
NZ297100A (en) * 1994-12-13 1997-10-24 Akira Matsuda 3'-substituted nucleoside derivatives; medicaments
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
WO2012006351A1 (en) 2010-07-08 2012-01-12 Life Technologies Corporation In situ chemiluminescent substrates and assays
JP2014516947A (ja) 2011-05-03 2014-07-17 ライフ テクノロジーズ コーポレーション フラッシュ・グロー型の１，２−ジオキセタン
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
SI3362461T1 (sl) 2015-10-16 2022-05-31 Modernatx, Inc. Analogi kape MRNA z modificirano fosfatno povezavo
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
WO2017120508A1 (en) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
SG11202012001YA (en) 2018-06-21 2021-01-28 Calithera Biosciences Inc Ectonucleotidase inhibitors and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LARS PETTER JORDHEIM 等: "Determination of the enzymatic activity of cytosolic 5-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》 *
PERIGAUD CG等: "Nucleoside analogues as chemotherapeutic agents: a review", 《NUCLEOSIDES&NUCLEOTIDES》 *
PETER L. BONATE 等: "Discovery and development of clofarabine: a nucleoside analogue for treating cancer", 《NATURE REVIEWS》 *
SANJAY BHATTARAI等: "α,β-Methylene-ADP (AOPCP) Derivatives and Analogues:Development of Potent and Selective ecto-5′-Nucleotidase (CD73)Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112888696A (zh) * 2018-06-21 2021-06-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
CN112888696B (zh) * 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法

Also Published As

Publication number Publication date
TWI766923B (zh) 2022-06-11
US20180186827A1 (en) 2018-07-05
KR102638592B1 (ko) 2024-02-19
IL267291B (en) 2022-12-01
TW201834665A (zh) 2018-10-01
CA3047988A1 (en) 2018-06-28
US20230002437A1 (en) 2023-01-05
IL267291B2 (en) 2023-04-01
US11034715B2 (en) 2021-06-15
MX383880B (es) 2025-03-14
US10570167B2 (en) 2020-02-25
IL267291A (en) 2019-08-29
AU2017382888B2 (en) 2021-12-23
AU2017382888A1 (en) 2019-06-20
NZ754171A (en) 2022-12-23
US20200223882A1 (en) 2020-07-16
JP7138351B2 (ja) 2022-09-16
BR112019012327A2 (pt) 2019-11-19
JP2020504735A (ja) 2020-02-13
WO2018119284A1 (en) 2018-06-28
EP3558998A4 (en) 2020-06-10
MX2019007243A (es) 2019-09-06
EP3558998A1 (en) 2019-10-30
KR20190114972A (ko) 2019-10-10

Similar Documents

Publication Publication Date Title
CN110402249A (zh) 外核苷酸酶抑制剂及其使用方法
CN110234656B (zh) 外核苷酸酶抑制剂及其使用方法
US12421273B2 (en) Ectonucleotidase inhibitors and methods of use thereof
CN114008048A (zh) 外核苷酸酶抑制剂及其使用方法
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
HK40049700B (zh) 外核苷酸酶抑制剂及其使用方法
HK40049700A (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017040

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230301

Address after: Kowloon, Hongkong, China

Applicant after: Deqi Medical Co.,Ltd.

Address before: California, USA

Applicant before: CALITHERA BIOSCIENCES, Inc.